European Medicines Agency jeopardizes investments in drug development
The heart of a marketing authorisation application is the pre-clinical and clinical data that proves the drug’s safety and efficacy. This data is collected through substantial investments in time and money. The current and proposed policies of the European Medicines Agency threaten the confidentiality, and hence the business value, of these investments.
Click on the link above to download this Jones Day briefing.
News from The Lawyer
Briefings from Jones Day
Jones Day operates a different training system to most City firms. Understanding how it works and why the firm doesn’t just follow the crowd is key to understanding whether it’s a system that’s for you.
For the past 10 months, the US Department of Justice and the Enforcement Division of the Securities and Exchange Commission have advised the public that they are in the process of drafting guidance for companies regarding the requirements of, and prohibitions within, the US Foreign Corrupt Practices Act.